Compass Pathways PLC (5Y6.MU)
- Business Wire
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
LONDON & NEW YORK, September 23, 2024--Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, announced today that executives from the management team will be participating in a fireside chat at the Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit on September 26, 2024 at 1:20pm ET.
- GlobeNewswire
Compass Pathways to participate in three investor conferences in September
LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following September investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference: fireside chat at 7:45 am ET on September 4, 2024, and host investor meetingsH. C. Wainwright 26th Annual Global Investment Conference: fireside chat at 9:
- Barrons.com
FDA Rejection of MDMA Therapy Isn’t End of Psychedelic-Drug Candidates
The Food and Drug Administration rejected Lykos’ application to treat PTSD with MDMA therapy. Atai, Compass Pathways, and MindMed are sliding in the wake of the decision.
